Continuous glucose monitoring and how it’s advancing diabetes care Gone are the days where a type 1 diabetes diagnosis meant a lifetime of finger pricking and injections. Today, almost half of the 4 million Americans living with type 1 diabetes use devices called continuous glucose monitors, or CGMs, to monitor their glucose and regulate their insulin levels in real-time. As the market for CGMs grows — to $5 billion in 2021, by some estimates — so too does the optimism that they will also be able to help manage the flood of unmanaged type 2 diabetes. In our latest report, written by STAT’s Katie Palmer, we’ve gathered our best intelligence on the burgeoning industry of CGM, and where it’s likely to head next. Get the report
About STAT Reports STAT Reports help business executives, researchers, consultants, and analysts navigate the ever-changing life sciences industry. Each report provides deep analysis of a particular issue in health care. Pick and purchase the reports that are most relevant to you. Learn More
Other topics include: | 
No comments